# TLX250 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tlx250

> TLX250, sponsored by Telix Pharmaceuticals Ltd (TLX), received a complete response letter from the FDA; the decision is dated August 4, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TLX250 |
| Codes | TLX250 |
| Sponsor | Telix Pharmaceuticals Ltd (TLX) https://sec-api.dev/companies/tlx/catalysts |
| Indications | diverse range of solid tumors for potential therapeutic and diagnostic applications, ccrcc |
| Modality |  |
| FDA designations | breakthrough, fast track, priority review |

## Timeline

### Jul 2023: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: diverse range of solid tumors for potential therapeutic and diagnostic applications.
- First seen 2025-02-24, last confirmed 2026-02-20.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "In June 2023, we dosed the first patient in the Phase 2 STARBURST trial of TLX250-Px exploring CAIX expression in patients with a diverse range of solid tumors for potential therapeutic and diagnostic applications." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm
- SEC Form 10-K (accession 0001628280-26-009943): "In June 2023, we dosed the first patient in the Phase 2 STARBURST trial of TLX250-Px exploring CAIX expression in patients with a diverse range of solid tumors for potential therapeutic and diagnostic applications." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm
- SEC Form 10-K (accession 0001140361-25-005562): "In July 2023, we dosed the first patient in the Phase 2 STARBURST trial of TLX250-CDx exploring CAIX expression in patients with a diverse range of solid tumors for potential therapeutic and diagnostic applications." https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm

### Dec 2023: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-02-19, last confirmed 2026-02-19.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "We submitted a BLA for TLX250-Px to the FDA for regulatory approval in December 2023 for characterization of masses as ccRCC." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "We submitted a BLA for TLX250-Px to the FDA for regulatory approval in December 2023." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm

### Nov 2024: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: ccRCC.
- First seen 2025-02-24, last confirmed 2026-02-20.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "In November 2024, we dosed the first patient in the Phase 3 ZIRCON-CP study of TLX250-Px PET imaging of ccRCC in Chinese patients." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm
- SEC Form 10-K (accession 0001628280-26-009943): "In November 2024, we dosed the first patient in the Phase 3 ZIRCON-CP study of TLX250-Px PET imaging of ccRCC in" https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm
- SEC Form 10-K (accession 0001140361-25-005562): "In November 2024, we dosed the first patient in the Phase 3 ZIRCON-CP study of TLX250-CDx PET imaging of ccRCC in Chinese patients." https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "In October 2024, we announced that we dosed the first patient in the Phase 2 CA-NINE trial, which is an investigator- initiated Phase 2 trial evaluating TLX250-Px in patients with ccRCC after surgery." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm
- SEC Form 10-K (accession 0001628280-26-009943): "In October 2024, we announced that we dosed the first patient in the Phase 2 CA-NINE trial, which is an investigator- initiated Phase 2 trial evaluating TLX250-Px in patients with ccRCC after surgery." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm
- SEC Form 10-K (accession 0001140361-25-005562): "In October 2024, we announced that we dosed the first patient in the Phase 2 CA-NINE trial, which is an investigator-initiated Phase 2 trial evaluating TLX250-CDx in patients with ccRCC after surgery." https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm

### Dec 2024: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-02-20, last confirmed 2026-02-20.
- SEC Form 10-K (accession 0001628280-26-009943): "In December 2024 we resubmitted our BLA to the FDA for TLX250-Px, and the" https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm

### Dec 2024: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-02-19, last confirmed 2026-02-20.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "In December 2024 we resubmitted our BLA to the FDA for TLX250-Px, and the FDA accepted our application in February 2025." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm
- SEC Form 10-K (accession 0001628280-26-009943): "In December 2024 we resubmitted our BLA to the FDA for TLX250-Px, and the FDA accepted our application in February 2025." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm

### August 4, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-08-28, last confirmed 2026-02-19.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "In August 2025, the FDA issued a Complete Response Letter ("CRL"), citing deficiencies relating to the Chemistry, Manufacturing, and Controls ("CMC") package." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "In August 2025, the FDA issued a Complete Response Letter ("CRL") citing deficiencies relating to the Chemistry, Manufacturing, and Controls ("CMC") package." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-009887): "In August 2025, the FDA issued a CRL, citing deficiencies relating to the CMC package." https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm
- Press release filed with the SEC (EX-99) (accession 0002007191-25-000065): "Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has received a Complete Response Letter (CRL) from the United States (U.S.) Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zircaix®1, 89Zr-DFO-girentuximab), an investigational PET2 agent for the diagnosis and characterization of renal masses as clear cell renal cell carcinoma (ccRCC)." https://www.sec.gov/Archives/edgar/data/2007191/000200719125000065/zircprcrl.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tlx250.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TLX250 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tlx250

```bibtex
@misc{secapidev_pdufa_tlx250_20261116,
  title        = {TLX250 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tlx250}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tlx250_20261116","title":"TLX250 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tlx250","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
